Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
USE CASES
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
PatSnap Eureka Desktop
NEWAnalytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
NEWServices professionnels
Cabinets d'avocats
Sciences de la vie
Haute technologie
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport How IL-17A/F bispecific antibodies like bimekizumab are reshaping treatment of psoriasis, psoriatic arthritis, and hidradenitis suppurativa. Patent landscape analysis.
Article | Rapport How to implement OPC UA over TSN for deterministic real-time communication in smart factories — patent analysis covering CUC/CNC, gate scheduling, and PTP sync.
Article | Rapport Electroactive polymer actuator patent landscape 2026: key assignees, emerging clusters, and strategic IP implications across medical, haptics, and robotics.
Article | Rapport How to implement OPC UA over TSN in smart factories: protocol architecture, CUC/CNC configuration, gate scheduling, and timing sync — drawn from 40+ patents.
Article | Rapport Tezepelumab, itepekimab, and next-gen bispecific alarmin blockers are reshaping severe asthma biologics. Explore the patent landscape and pipeline signals.
Article | Rapport Explore the 2026 bispecific antibody manufacturing patent landscape: Fc engineering, continuous bioprocessing, Chinese biotech filings, and emerging format strategies.
Article | Rapport A deep analysis of bispecific antibody manufacturing patent landscape 2026: Fc engineering, continuous bioprocessing, Chinese biotech filings, and emerging format strategies.
Article | Rapport How next-generation anti-amyloid antibodies, bispecific platforms, and tau-targeting modalities are reshaping the Alzheimer's disease pipeline after lecanemab's approval.
Article | Rapport How psilocybin, 5-MeO-DMT, LSD and novel analogues are reshaping the patent landscape for treatment-resistant depression and PTSD. Deep-dive analysis.
Article | Rapport How foundation model fine-tuning transforms PCB automated optical inspection: patent intelligence covering hybrid pipelines, CLIP-based prompt learning, and continual learning.
Article | Rapport Mapping the 2026 autonomous robotic surgery patent landscape: AI navigation, collision avoidance, tendon-drive control, and the assignees shaping surgical autonomy.
Article | Rapport Small molecules, cyclic peptides, oral ASOs and combination strategies targeting PCSK9 in ASCVD — a patent-driven analysis of the next-generation pipeline.
Article | Rapport How foundation model fine-tuning transforms PCB automated optical inspection: patent intelligence across 40+ filings from Siemens, Bosch, Tsinghua & more.
Article | Rapport A 2026 patent landscape analysis of autonomous robotic surgery: AI navigation, collision avoidance, tendon-drive control, and the top assignees shaping the field.
Article | Rapport How milvexian and asundexian are reshaping stroke prevention by targeting Factor XIa — Phase II data, patent landscape, and pipeline strategy decoded.